Cyclacel Pharmaceuticals to Present at the 15th Annual BIO CEO & Investor Conference

Cyclacel Pharmaceuticals to Present at the 15th Annual BIO CEO & Investor
Conference

BERKELEY HEIGHTS, N.J., Feb. 4, 2013 (GLOBE NEWSWIRE) -- Cyclacel
Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company)
today announced that the Company will present at the 15th Annual BIO CEO &
Investor Conference, being held at the Waldorf Astoria Hotel in New York City,
New York. Spiro Rombotis, President and Chief Executive Officer, will provide
an overview of the Company and its progress in key programs on Monday,
February 11, 2013 at 2:30 p.m. Eastern.

Cyclacel's presentation will be webcast live and archived for 90 days on the
Corporate Presentations page of the Cyclacel website at www.cyclacel.com.

About the BIO CEO & Investor Conference

Now in its fifteenth year, the BIO CEO & Investor Conference is the largest
independent investor conference for the life sciences industry focused on
publicly-traded biotechnology companies. The meeting provides a forum where
institutional investors, industry analysts, and executives from leading global
pharmaceutical and biotechnology companies will discuss investment
opportunities in the biotechnology industry. This year's meeting will feature
issues-oriented plenary sessions, company presentations, one-on-one meetings
and educational sessions focused on current business trends in the life
sciences.

About Cyclacel Pharmaceuticals, Inc.

Cyclacel is a biopharmaceutical company developing oral therapies that target
the various phases of cell cycle control for the treatment of cancer and other
serious diseases. The Company's most advanced oral product candidate,
sapacitabine, is the subject of SEAMLESS, a Phase 3 trial being conducted
under an SPA with the FDA as front-line treatment of acute myeloid leukemia
(AML) in the elderly and Phase 2 studies for AML, myelodysplastic syndromes
(MDS), chronic lymphocytic leukemia (CLL) and solid tumors including breast,
lung, ovarian and pancreatic cancer. Cyclacel's pipeline includes seliciclib,
a CDK inhibitor, in Phase 2 for lung and nasopharyngeal cancer and in Phase 1
in combination with sapacitabine; and CYC065, a second generation CDK
inhibitor, in IND-directed development. Cyclacel's strategy is to build a
diversified biopharmaceutical business focused in hematology and oncology
based on a development pipeline of novel drug candidates. Please visit
www.cyclacel.com for additional information.

Forward-looking Statements

This news release contains certain forward-looking statements that involve
risks and uncertainties that could cause actual results to be materially
different from historical results or from any future results expressed or
implied by such forward-looking statements. Such forward-looking statements
include statements regarding, among other things, the efficacy, safety and
intended utilization of Cyclacel's product candidates, the conduct and results
of future clinical trials, plans regarding regulatory filings, future research
and clinical trials and plans regarding partnering activities. Factors that
may cause actual results to differ materially include the risk that product
candidates that appeared promising in early research and clinical trials do
not demonstrate safety and/or efficacy in larger-scale or later clinical
trials, trials may have difficulty enrolling, Cyclacel may not obtain approval
to market its product candidates, the risks associated with reliance on
outside financing to meet capital requirements, and the risks associated with
reliance on collaborative partners for further clinical trials, development
and commercialization of product candidates. You are urged to consider
statements that include the words "may," "will," "would," "could," "should,"
"believes," "estimates," "projects," "potential," "expects," "plans,"
"anticipates," "intends," "continues," "forecast," "designed," "goal," or the
negative of those words or other comparable words to be uncertain and
forward-looking. For a further list and description of the risks and
uncertainties the Company faces, please refer to our most recent Annual Report
on Form 10-K and other periodic and other filings we file with the Securities
and Exchange Commission and are available at www.sec.gov. Such forward-looking
statements are current only as of the date they are made, and we assume no
obligation to update any forward-looking statements, whether as a result of
new information, future events or otherwise.

© Copyright 2013 Cyclacel Pharmaceuticals, Inc.All Rights Reserved.The
Cyclacel logo and Cyclacel® are trademarks of Cyclacel Pharmaceuticals, Inc.

CONTACT: Cyclacel Pharmaceuticals, Inc.
         Investors/Media: Corey Sohmer, (908) 517-7330,
         csohmer@cyclacel.com